专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20050287138A1 CCR4-specific antibody composition 审中-公开
标题翻译： CCR4特异性抗体组成
公开(公告)号：US20050287138A1
公开(公告)日：2005-12-29
申请号：US10959310
申请日：2004-10-07
申请人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
发明人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , C07K2317/41 , C07K2317/732
摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
摘要翻译：本发明提供一种抗体组合物，其包含特异性结合人类CC趋化因子受体4（CCR4）的抗体分子，并且在Fc区具有复合型N-糖苷连接的糖链，其中复合型N-糖苷连接的糖链在糖链的还原端具有岩藻糖不与N-乙酰葡糖胺结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

62. 发明授权

US5580740A Antihuman pulmonary adenocarcinoma monoclonal antibody 失效
标题翻译：抗人肺腺癌单克隆抗体
公开(公告)号：US5580740A
公开(公告)日：1996-12-03
申请号：US422660
申请日：1995-04-14
申请人： Hajime Yoshida , Kenya Shitara
发明人： Hajime Yoshida , Kenya Shitara
IPC分类号： A61K38/00 , C07K16/30 , G01N33/574 , C07K16/00
CPC分类号： C07K16/30 , A61K38/00
摘要： An antihuman pulmonary adenocarcinoma monoclonal antibody ALC-390 and a process for producing thereof are disclosed. This monoclonal antibody, which belongs to IgG class and is reactive with human pulmonary adenocarcinoma cell membranes and recognizes protein as the antigen, is highly useful in the pathological diagnosis of pulmonary adenocarcinoma and in the treatment of the same.
摘要翻译：公开了一种抗人肺腺癌单克隆抗体ALC-390及其生产方法。属于IgG类并且与人肺腺癌细胞膜反应并识别蛋白质作为抗原的单克隆抗体在肺腺癌的病理诊断和治疗中是非常有用的。

63. 发明授权

US08491902B2 Medicament comprising recombinant antibody against chemokine receptor CCR4 有权
标题翻译：包含针对趋化因子受体CCR4的重组抗体的药物
公开(公告)号：US08491902B2
公开(公告)日：2013-07-23
申请号：US10581413
申请日：2004-12-03
申请人： Kenya Shitara , Rinpei Niwa , So Ohta , Yuka Sasaki , Junji Kanazawa , Toshihiko Ishii , Shiro Akinaga
发明人： Kenya Shitara , Rinpei Niwa , So Ohta , Yuka Sasaki , Junji Kanazawa , Toshihiko Ishii , Shiro Akinaga
IPC分类号： A61K39/395
CPC分类号： A61K31/675 , A61K31/437 , A61K31/475 , A61K31/519 , A61K31/704 , A61K31/7048 , A61K38/193 , A61K38/2013 , A61K38/2086 , A61K38/212 , A61K39/395 , A61K39/39558 , A61K45/06 , C07K16/2866 , A61K2300/00
摘要： A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.
摘要翻译：提供了具有比通过施用针对人CC趋化因子受体4或其抗体片段或单独的试剂的重组抗体提供的治疗效果更高的治疗效果的药物。

64. 发明申请

US20090226399A1 MEDICAMENTS COMPRISING GENE RECOMBINANT ANTIBODY AGAINST GANGLIOSIDE GD3 审中-公开
标题翻译：含有抗坏血酸GD3基因重组抗体的药物
公开(公告)号：US20090226399A1
公开(公告)日：2009-09-10
申请号：US12420142
申请日：2009-04-08
申请人： Kenya Shitara , Rinpei Niwa , Junji Kanazawa , Masao Asada
发明人： Kenya Shitara , Rinpei Niwa , Junji Kanazawa , Masao Asada
IPC分类号： A61K39/395 , A61K38/21 , A61P35/00
CPC分类号： C07K16/28 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/732 , C07K2317/734 , A61K2300/00
摘要： In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired.An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.
摘要翻译：为了在治疗恶性肿瘤，特别是黑素瘤中获得高治疗效果，期望具有较少副作用的新治疗方法或可以在常规剂量的试剂中提供更高治疗效果的新治疗方法。本发明的目的是提供一种可以提供比单独的针对神经节苷脂GD3的基因重组抗体或其单独的抗体片段的任何一种更高的治疗效果的药物，以及激活免疫组分细胞的物质和具有抗肿瘤活性的物质通过将基因重组抗体与神经节苷脂GD3或其抗体片段与激活免疫组分细胞的物质和具有抗肿瘤活性的物质中的至少一种组合。此外，预期药物可以减轻在给予单个单一药剂的情况下是问题的副作用。

65. 发明申请

US20080213266A1 Method for Treating CCR4-Related Diseases 审中-公开
标题翻译：治疗CCR4相关疾病的方法
公开(公告)号：US20080213266A1
公开(公告)日：2008-09-04
申请号：US11969555
申请日：2008-01-04
申请人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
发明人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K16/2866 , C07K2317/41 , C07K2317/732
摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
摘要翻译：本发明提供一种抗体组合物，其包含特异性结合人类CC趋化因子受体4（CCR4）的抗体分子，并且在Fc区具有复合型N-糖苷连接的糖链，其中复合型N-糖苷连接的糖链在糖链的还原端具有岩藻糖不与N-乙酰葡糖胺结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

66. 发明申请

US20070020263A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 有权
标题翻译：含有针对趋化因子受体ccr4的转基因抗体的药物
公开(公告)号：US20070020263A1
公开(公告)日：2007-01-25
申请号：US10581413
申请日：2004-12-03
申请人： Kenya Shitara , Rinpei Niwa , So Ohta , Yuka Sasaki , Junji Kanazawa , Toshihiko Ishii , Shiro Akinaga
发明人： Kenya Shitara , Rinpei Niwa , So Ohta , Yuka Sasaki , Junji Kanazawa , Toshihiko Ishii , Shiro Akinaga
IPC分类号： A61K39/395
CPC分类号： A61K31/675 , A61K31/437 , A61K31/475 , A61K31/519 , A61K31/704 , A61K31/7048 , A61K38/193 , A61K38/2013 , A61K38/2086 , A61K38/212 , A61K39/395 , A61K39/39558 , A61K45/06 , C07K16/2866 , A61K2300/00
摘要： A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.
摘要翻译：提供了具有比通过施用针对人CC趋化因子受体4或其抗体片段或单独的试剂的重组抗体提供的治疗效果更高的治疗效果的药物。

67. 发明申请

US20050226867A1 IL-5R-specific antibody composition 审中-公开
标题翻译： IL-5R特异性抗体组成
公开(公告)号：US20050226867A1
公开(公告)日：2005-10-13
申请号：US10959326
申请日：2004-10-07
申请人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara , Masamichi Koike
发明人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara , Masamichi Koike
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
摘要翻译：本发明提供一种抗体组合物，其包含特异性结合人白细胞介素-5受体α链并在Fc区具有复合型N-糖苷连接的糖链的抗体分子，其中复合型N-糖苷连接的糖链具有岩藻糖在糖链的还原端不与N-乙酰氨基葡萄糖结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

68. 发明申请

US20110236374A1 GENETICALLY RECOMBINANT ANTIBODY COMPOSITION CAPABLE OF BINDING SPECIFICALLY TO GANGLIOSIDE GM2 审中-公开
标题翻译：具有特异性结合GANIOSIDE GM2的基因重组抗体组合物
公开(公告)号：US20110236374A1
公开(公告)日：2011-09-29
申请号：US12524215
申请日：2008-01-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： A61K39/395 , C12N5/10 , C07K16/18 , C07H21/04 , A61P35/00
CPC分类号： C07K16/44 , C07K16/2887 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a genetically recombinant antibody composition which specifically binds to ganglioside GM2, which has higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译：本发明涉及特异性结合神经节苷脂GM2的遗传重组抗体组合物，神经节苷脂GM2比人IgG1抗体和人IgG3抗体具有更高的补体依赖性细胞毒活性，其中包含人Fc区中的CH2结构域的多肽 IgG1抗体被包含与Kabat等人所指示的EU指数所示的人IgG3抗体相同位置的氨基酸序列的多肽代替; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

69. 发明授权

US07994290B2 Effector function enhanced recombinant antibody composition 有权
标题翻译：效应功能增强重组抗体组成
公开(公告)号：US07994290B2
公开(公告)日：2011-08-09
申请号：US12019160
申请日：2008-01-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： C12P21/08 , C12P21/04 , A61K39/00
CPC分类号： C07K16/2887 , A61K2039/505 , C07K16/00 , C07K16/2893 , C07K2317/24 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译：本发明涉及一种重组抗体组合物，其是人IgG1抗体，其包含CH2结构域，其中由Kabat等人在EU指数表示的位置276和339处的氨基酸。被替换为其他氨基酸，并且在氨基酸被替换之前具有比包含CH2结构域的抗体更好的补体依赖性细胞毒活性; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将DNA引入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。

70. 发明授权

US07691568B2 Antibody composition-containing medicament 有权
标题翻译：含抗体组合物的药物
公开(公告)号：US07691568B2
公开(公告)日：2010-04-06
申请号：US10409598
申请日：2003-04-09
申请人： Rinpei Niwa , Kenya Shitara
发明人： Rinpei Niwa , Kenya Shitara
IPC分类号： A61K39/395
CPC分类号： C07K16/2896 , C07K16/18 , C07K16/2866 , C07K16/44 , C07K2317/41 , C07K2317/732
摘要： A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.
摘要翻译：一种用于治疗不能用含有作为活性成分的药物治疗患者的药物，该抗体组合物是由对抗凝集素不敏感的细胞产生的抗体组合物，所述抗体组合物识别岩藻糖的1位与6-位N- 乙酰葡糖胺在复合N-糖苷连接的糖链中通过α-键包含作为活性成分的抗体组合物，该抗体组合物是由对能够鉴定其中1位的岩藻糖的糖链的凝集素具有抗性的细胞产生的抗体组合物通过复合N-糖苷连接的糖链中的α-键与还原末端的N-乙酰葡糖胺的6-位结合，以及通过使用该药物对患者进行筛选的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式